EGCG–Dopamine–Tryptophan Nanoparticles (EDTNPs)

Why in News

Researchers at the Institute of Nano Science and Technology (INST), Mohali have developed a multifunctional nanoplatform that shows promise in slowing Alzheimer’s disease progression, improving memory, and supporting cognitive functions.

Background

• Alzheimer’s disease is a growing global public health challenge
• Ageing populations are increasing the burden on healthcare systems
• Existing treatments largely offer symptomatic relief, not disease modification

About the New Nanoplatform

• The therapy combines three bioactive molecules into a single nanoparticle system:
  • Epigallocatechin-3-gallate (EGCG): A polyphenol antioxidant found in green tea
  • Dopamine: A neurotransmitter linked to mood, learning, and cognition
  • Tryptophan: An essential amino acid important for brain health
• These are integrated into EGCG–Dopamine–Tryptophan Nanoparticles (EDTNPs)

Mechanism of Action

The nanoparticles are designed to simultaneously target four key hallmarks of Alzheimer’s disease:

1. Amyloid protein aggregation
2. Oxidative stress
3. Neuroinflammation
4. Neuronal degeneration

This multi-targeted approach improves therapeutic effectiveness compared to single-target drugs.

Enhanced Innovation: BDNF Functionalisation

• Researchers further enhanced the platform by incorporating:
  • Brain-Derived Neurotrophic Factor (BDNF)
• BDNF is crucial for:
  • Neuron survival
  • Neuronal growth
  • Synaptic plasticity and memory formation
• Resulting formulation:
  • BDNF-functionalised EDTNPs
  • Offers improved neuroprotection and cognitive support

Source: DD News